These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 21861932)
1. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer. Singh PP; Joshi S; Russell PJ; Nair S; Khatri A BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932 [TBL] [Abstract][Full Text] [Related]
2. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer. Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822 [TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036 [TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227 [TBL] [Abstract][Full Text] [Related]
5. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Voeks D; Martiniello-Wilks R; Madden V; Smith K; Bennetts E; Both GW; Russell PJ Gene Ther; 2002 Jun; 9(12):759-68. PubMed ID: 12040457 [TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359 [TBL] [Abstract][Full Text] [Related]
7. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gadi VK; Alexander SD; Kudlow JE; Allan P; Parker WB; Sorscher EJ Gene Ther; 2000 Oct; 7(20):1738-43. PubMed ID: 11083495 [TBL] [Abstract][Full Text] [Related]
8. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. Guillen KP; Kurkjian C; Harrison RG J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949 [TBL] [Abstract][Full Text] [Related]
9. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. Martiniello-Wilks R; Dane A; Voeks DJ; Jeyakumar G; Mortensen E; Shaw JM; Wang XY; Both GW; Russell PJ J Gene Med; 2004 Jan; 6(1):43-54. PubMed ID: 14716676 [TBL] [Abstract][Full Text] [Related]
10. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Martiniello-Wilks R; Garcia-Aragon J; Daja MM; Russell P; Both GW; Molloy PL; Lockett LJ; Russell PJ Hum Gene Ther; 1998 Jul; 9(11):1617-26. PubMed ID: 9694160 [TBL] [Abstract][Full Text] [Related]
11. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. Hong JS; Waud WR; Levasseur DN; Townes TM; Wen H; McPherson SA; Moore BA; Bebok Z; Allan PW; Secrist JA; Parker WB; Sorscher EJ Cancer Res; 2004 Sep; 64(18):6610-5. PubMed ID: 15374975 [TBL] [Abstract][Full Text] [Related]
12. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Blumenthal RD; Leone E; Goldenberg DM; Rodriguez M; Modrak D Int J Cancer; 2004 Jan; 108(2):293-300. PubMed ID: 14639618 [TBL] [Abstract][Full Text] [Related]
13. Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside. Deharvengt S; Wack S; Uhring M; Aprahamian M; Hajri A Pancreas; 2004 Mar; 28(2):E54-64. PubMed ID: 15028961 [TBL] [Abstract][Full Text] [Related]
14. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? Nawa A; Tanino T; Luo C; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Nishiyama Y; Kikkawa F Anticancer Agents Med Chem; 2008 Feb; 8(2):232-9. PubMed ID: 18288924 [TBL] [Abstract][Full Text] [Related]
15. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. Krais JJ; De Crescenzo O; Harrison RG PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491 [TBL] [Abstract][Full Text] [Related]
16. Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells. Messina M; Yu DM; Both GW; Molloy PL; Robinson BG J Clin Endocrinol Metab; 2003 Mar; 88(3):1310-8. PubMed ID: 12629124 [TBL] [Abstract][Full Text] [Related]
17. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Liu E; Liu Z; Zhou Y Int J Clin Exp Pathol; 2015; 8(4):3803-10. PubMed ID: 26097562 [TBL] [Abstract][Full Text] [Related]
18. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334 [TBL] [Abstract][Full Text] [Related]
19. Evaluating antitumor activity of Escherichia coli purine nucleoside phosphorylase against head and neck patient-derived xenografts. Rab R; Ehrhardt A; Achyut BR; Joshi D; Gilbert-Ross M; Huang C; Floyd K; Borovjagin AV; Parker WB; Sorscher EJ; Hong JS Cancer Rep (Hoboken); 2023 Feb; 6(2):e1708. PubMed ID: 36253876 [TBL] [Abstract][Full Text] [Related]
20. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH Cancer Gene Ther; 2007 Mar; 14(3):279-86. PubMed ID: 17218950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]